Drug Profile
Lutikizumab - AbbVie
Alternative Names: ABT-981Latest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Anti-inflammatories; Bispecific antibodies; Immunoglobulins; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hidradenitis suppurativa; Ulcerative colitis
- No development reported Osteoarthritis
Most Recent Events
- 26 Mar 2024 Phase-II clinical trials in Ulcerative colitis in USA (IV) (NCT06257875)
- 26 Mar 2024 Phase-II clinical trials in Ulcerative colitis in USA (SC) (NCT06257875)
- 26 Feb 2024 AbbVie completes phase I pharmacokinetics trial (In volunteers) in US (SC) (NCT06067568)